| 1 |
35221836 | Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management. | 2022 |
1 |
| 2 |
33980578 | An oral antisense oligonucleotide for PCSK9 inhibition. | 2021 May 12 |
2 |
| 3 |
32415571 | Single-Strand DNA-Like Oligonucleotide Aptamer Against Proprotein Convertase Subtilisin/Kexin 9 Using CE-SELEX: PCSK9 Targeting Selection. | 2020 Aug |
2 |
| 4 |
29692249 | PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol. | 2019 |
1 |
| 5 |
28784313 | PCSK9 inhibition in the management of familial hypercholesterolemia. | 2018 Jan |
2 |
| 6 |
29574075 | Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide. | 2018 May - Jun |
1 |
| 7 |
30317986 | Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives. | 2018 |
1 |
| 8 |
28112180 | Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives. | 2017 Mar |
1 |
| 9 |
28395986 | A decade of progress on the genetic basis of coronary artery disease. Practical insights for the internist. | 2017 Jun |
1 |
| 10 |
27133571 | Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. | 2016 Aug |
1 |
| 11 |
25791168 | RNA therapeutics inactivate PCSK9 by inducing a unique intracellular retention form. | 2015 May |
1 |
| 12 |
24993279 | PCSK9 and LDLR The Yin-Yang in the Cellular Uptake of Cholesterol. | 2014 Jul 1 |
1 |
| 13 |
23129439 | LDL Lowering After Acute Coronary Syndrome: Is Lower Better? | 2013 Feb |
1 |
| 14 |
23338726 | PCSK9 Inhibitors: potential in cardiovascular therapeutics. | 2013 Mar |
1 |
| 15 |
23561896 | Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. | 2013 Oct |
2 |
| 16 |
23913122 | New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? | 2013 Dec |
1 |
| 17 |
23932550 | New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. | 2013 Aug |
1 |
| 18 |
22108858 | PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. | 2012 Feb |
5 |
| 19 |
22493980 | Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia. | 2012 May |
1 |